Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: high affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment.

Somatostatin receptor-4 (SST) is highly expressed in brain regions affiliated with learning and memory. SST agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST agonist lead optimization is presented herein.